Axsome Therapeutics (AXSM) Misses Q1 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Axsome Therapeutics (AXSM) Misses Q1 EPS by 3c

Axsome Therapeutics Reports First Quarter 2016 Financial Results

May 11, 2016 4:42 PM EDT

NEW YORK, May 11, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended March 31, 2016.

We continued to make progress with our lead product candidates, AXS-02 and AXS-05, over the past quarter, said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome Therapeutics. We recently advanced AXS-02 into a registration trial in knee osteoarthritis associated with bone marrow lesions. We also received positive guidance from the FDA on... More